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To the Editor: In-stent thrombosis (IST) remains a major challenge
in interventional cardiology. Trials comparing balloon angioplasty
with coronary stenting demonstrated an IST incidence 5% (1,2).
Improved stent deployment combined with dual antiplatelet ther-
apy reduced the incidence to 0.5% to 2% (3–6). Aside from
appropriate antiplatelet therapy, high-pressure balloon inflation,
optimal lumen diameter, the absence of proximal or distal flow-
limiting lesions, and endothelial stent surface restoration, are all
believed to protect against IST (7). Factors that increase IST risk
include long stents, stent malapposition, residual dissections, and
aspirin or thienopyridine resistance (8). Although malignancy is
associated with venous thrombosis, little is known about increased
IST in cancer patients (9). Because cancer patients are now
commonly referred, we tested the notion that cancer would
increase the risk for IST. We reviewed the hospital records of all
patients undergoing bare-metal stenting between January 1997 and
May 2007. We identified IST patients and cancer in our comput-
erized database. We then reviewed the angiograms and medical
records. Patients who received drug-eluted stents or who under-
went left main stem stenting were excluded. Angiographic criteria
of stent thrombosis were partial or complete occlusion. We
expressed continuous data as mean  SD. We expressed discrete
variables as counts or percentages with chi-square analysis. We
conducted group comparisons for continuous data with unpaired
2-sided t tests.
Table 1 summarizes the demographic and clinical characteristics
of the patients. We found 108 patients with cancer; IST occurred
in 55 of 7,081 patients without known malignancies (0.78%) and
in 6 of 108 cancer patients (5.56%; chi-square  26.86, p 
0.000001, odds ratio 7.10, 95% confidence interval 2.70 to 17.61).
Median time to IST was 7 days in cancer patients versus 4 days in
control subjects. In patients without malignancies, the culprit
lesions were located in the left anterior descending coronary artery
(LAD) in 40%, the left circumflex coronary artery (LCX) in 31%,
and the right coronary artery (RCA) in 30%. The corresponding
vessels in the 6 cancer patients with IST were 3 in the LAD, 1 in
the LCX, and 2 in the RCA, although the numbers are too small
to identify any one vessel. One patient in each group had
discontinued the recommended dual antiplatelet therapy. Because
IST is associated with stent size, we compared stent diameter and
length. The average stent diameter was 2.67  0.26 mm (p 
0.85) in cancer patients versus 2.64  0.50 mm (p  NS) in
controls. However, there was a tendency to implant shorter stents
in the cancer patients; the average stent length was 18.30  0.26
mm (p  0.06) versus 20.90  0.29 mm (p  NS) in the control
group. The stenting procedures were elective in 56% of controls,
compared with 50% in cancer patients. Notably, all 6 IST cancer
patients had solid tumors; none had leukemia, lymphoma, or
multiple myeloma. The tumors were 3 lung cancers, 1 cervical
cancer, 1 breast cancer, and 1 colon cancer.
This brief retrospective survey supported our clinical impression
that cancer patients have more IST than expected. The issue is
important because cardiological advances coupled with improved
prognosis for cancer patients will increase the patient number
accordingly. Furthermore, clinicians understand that many cancer
patients have a better prognosis than heart failure or renal failure
patients. Thus, the numbers of cancer patients receiving cardio-
vascular interventions will increase.
Cancer is an acquired thrombophilic condition (10). Thus,
increased IST in cancer patients should not evoke surprise. Cancer
patients commonly present with a hypercoagulable state, even in
the absence of thrombosis. Furthermore, clotting activation may
play a role in tumor progression. The pathogenesis of thrombosis
in cancer is multifactorial; however, a relevant role is attributed to
the tumor cell capacity to interact with and activate the host
hemostatic system. The prothrombotic action of antitumor ther-
apies is also important. Thrombotic events can influence the
morbidity and mortality of the underlying disease.
Demographic and Clinical Parameter of the Patients
Table 1 Demographic and Clinical Parameter of the Patients
CAD (n  7,081) CAD With Concomitant Malignant Disease (n  108)
No IST (n  7,026) IST (n  55) No IST (n  102) IST (n  6)
Age, yrs, male/female 62.9  10.6/68.0  10.5 63.0  12.2/63.8  8.5 67.0  11.3/67.0  8.8 70.0  6.7/76.0  5.7
Gender, male (%) 5,241 (74.6) 39 (70.9) 84 (82.4) 4 (66.7)
Diabetes mellitus, n (%) 1,613 (23.0) 14 (25.4) 21 (20.6) 1 (16.7)
Hypertension, n (%) 4,497 (64.0) 28 (50.9) 52 (51.0) 3 (50.0)
Hypercholesterolemia, n (%) 3,510 (50.0) 27 (49.1) 37 (36.3) 3 (50.0)
Aspirin, n (%) 5,690 (81.0) 44 (80.0) 83 (81.4) 4 (66.7)
Clopidogrel, n (%) 4,545 (64.70) 37 (67.3) 71 (69.6) 5 (83.3)
Ticlopidine, n (%) 1,370 (19.5) 14 (25.5) 11 (10.9) 1 (16.7)
Phenprocoumon, n (%) 689 (9.8) 7 (12.7) 6 (5.9) 1 (16.7)
CAD  coronary artery disease; IST  in-stent thrombosis.
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Preventing thrombotic complications in cancer patients is
highly relevant above-and-beyond IST. New approaches in cancer
patients have been investigated and the hypothesis that strategies
to inhibit clotting mechanism may favorably affect malignant
disease is gaining interest. Evidence-based strategies are being
developed to treat cancer patients with venous thromboembolism.
Phenprocoumon (warfarin and derivates) is problematic in cancer
patients because of unpredictable responses and variable efficacy.
Hull et al. (11) recently reported a multicenter, randomized,
open-label clinical trial using objective outcome measures compar-
ing long-term therapeutic low molecular weight heparin subcuta-
neously to warfarin therapy in cancer patients. Bleeding compli-
cations were the same. However, 16% of the warfarin group
developed thrombosis recurrence, compared with 7% in the low-
molecular-weight heparin group.
We are uncertain how stented cancer patients should be best
treated. Five of 6 developed IST despite optimal antiplatelet
therapy. Whether or not these patients should receive subcutane-
ous low molecular weight heparin, as did the cancer patients in the
trial by Hull et al. (11), is unknown. We pose the question of how
cancer patients will respond to drug-eluting stents. These stents
behave differently to endothelial repair. We have not placed such
stents in cancer patients. Consideration could also be given to treat
such high-risk patients with balloon dilatation alone without
stenting. Surveillance studies are necessary to address this impor-
tant question.
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Letters to the Editor
Debating About a Registry
to Define the Best Invasive
Treatment for Obstructive
Hypertrophic Cardiomyopathy
Should It Also Include
Obstructive Patients Medically Treated?
We have read with great interest the Viewpoint by Olivotto et al.
(1) that recently was published in the Journal. The authors have
convincingly demonstrated that a randomized prospective trial
comparing the results of these 2 techniques is not feasible, because
it would require the enrollment of more than 30,000 patients with
hypertrophic cardiomyopathy. We agree with their conclusion that
this issue can only be addressed by a large international multicenter
registry.
However, in our opinion, the discussion on the respective
advantages of surgical myectomy and alcohol septal ablation should
not distract from the crucial and, still controversial, question of
which patients are appropriate candidates for the myectomy
operation. Indeed, the international guidelines on hypertrophic
cardiomyopathy define candidates to myectomy as “both adults
and children with obstructive hypertrophic cardiomyopathy and
severe drug-refractory symptoms” (2). On the other hand, 2 recent
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